Faculty profile

Thomas Kislinger

Back to faculty

ProfessorDepartment of Medical BiophysicsUniversity of Toronto

Thomas Kislinger

Professor

Department of Medical Biophysics

Temerty Faculty of Medicine

University of Toronto

Toronto, Ontario, Canada

Canada Research Chair in Cancer Precision Medicine

Supervision signals

Professors usually supervise graduate students in their department's programs.
51 publications in the last five years, latest in 2026.
Senior (last) author on 19 recent papers, a sign of leading a research group.
Principal investigator on 15 research grants (15 CIHR), most recently in 2023.
Supervised 3 trainees who won CIHR awards, most recently in 2021.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

161

Publications

278

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Education

Profiles and links

University Profile Personal Website Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Toronto profile.

Proteomics Prostate Cancer Biomarker Cell Surface Patient-Derived Cancer Cells Personalized Medicine Therapy Prediction Biospecimen Repository

Latest papers

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.
Blood · 2026
Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome.
Journal of the National Cancer Institute · 2026 · senior author
Protocol for N-glycoproteomic enrichment of cancer cell-surface proteins in patient-derived xenografts.
STAR protocols · 2026 · senior author

All 161 publications

Latest funding

Using spatially defined analysis of TCR and BCR repertoires for analysis of immune evolution and lymphocyte clonal selection in pancreatic cancer
CIHR · 2025 · Co-investigator
$1,357,875
Mutations in pancreatic cancer cause increased sterol efflux and immune dysfunction in pancreatic cancer.
CIHR · 2025 · Co-investigator
$1,170,450
Primary prostate cancer cells as novel models for patient therapy prediction
CIHR · 2023 · Principal investigator
$883,576

All 26 grants and awards

From the 150 most recent of 161 publications.

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

Li X, Aguilar-Navarro AG, Nader M, Jahangiri S, Lee HS, Edun G, Gower M, Yang D, Fernandez M, Lin B, Oh D, Farhat S, Phillips DM, Bartman S, Murray D, Kaszuba C, Kossinna P, Kamath M, Whyne C, Schwartz G, Bajaj J, Kislinger T, Zhou BO, Coutu D, Akens M, Changoor A, Mallevaey T, Gaiti F, Jones C, Naik S, Minden M, Arruda A, Hitzler J, Lee KJ, Kim YM, Adams RH, Sivara KK, Tikhonova AN

Blood2026

DOI: 10.1182/blood.2025030946 PMID: 42008378

Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome.

Ha A, Arbet J, Qiu Z, Khoo A, Main BP, Govindarajan M, Waas M, Liu SK, Semmes OJ, Nyalwidhe JO, Boutros PC, Kislinger T

Journal of the National Cancer Institute2026Senior author

DOI: 10.1093/jnci/djag329 PMID: 42730607

Protocol for N-glycoproteomic enrichment of cancer cell-surface proteins in patient-derived xenografts.

Celejewski K, Govindarajan M, Waas M, Kislinger T

STAR protocols2026Senior author

DOI: 10.1016/j.xpro.2026.104799 PMID: 42647170

Identification of non-canonical peptides with moPepGen.

Zhu C, Liu LY, Ha A, Yamaguchi TN, Zhu H, Hugh-White R, Livingstone J, Patel Y, Kislinger T, Boutros PC

Nature biotechnology2026

DOI: 10.1038/s41587-025-02701-0 PMID: 40523945

METTL3-based epitranscriptomic editing screening identifies functional m6A sites in cancers.

Xu X, Wang Y, Zhu H, Lam M, Luo W, Teng M, Liu Y, Guo WY, Aastha A, Xu X, Chen S, Ci X, Wang S, Zeng Y, Zhu G, Kislinger T, Lupien M, Tsao MS, He HH

Nature cancer2026

DOI: 10.1038/s43018-026-01117-2 PMID: 41652220

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

Savage N, Grewal S, Shaikh MV, Zemp FJ, Mckenna D, Mikolajewicz N, Najem H, Pyczek J, Wei J, Taleb MAB

Nature20267 citations

DOI: 10.1038/s41586-026-10641-1

uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target

Maich WT, Shaikh MV, Puri A, Rossotti MA, Grewal S, Khanna A, Anand A, Mikolajewicz N, Seyfrid MP, McKenna DA

Science Translational Medicine20264 citations

DOI: 10.1126/scitranslmed.aea8381

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

Govindarajan M, Mejia-Guerrero S, Chafe SC, Khan S, Shi W, Waas M, Rossotti MA, Khoo A, Liu LY, Ignatchenko V

Cell Reports Medicine20262 citationsSenior author

DOI: 10.1016/j.xcrm.2025.102578

Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma.

Aastha A, Wilding H, Mikolajewicz N, Khan S, Ignatchenko V, De Macedo Filho LJM, Bhanja D, Remite-Berthet G, Heebner M, Glantz M, Mansouri A, Kislinger T

Neuro-oncology advances2025Senior author

DOI: 10.1093/noajnl/vdaf046 PMID: 40321620

Multi-Omics Study Reveals Nc886/vtRNA2-1 as a Positive Regulator of Prostate Cancer Cell Immunity.

Oliveira-Rizzo C, Colantuono CL, Fernández-Alvarez AJ, Boccaccio GL, Garat B, Sotelo-Silveira JR, Khan S, Ignatchenko V, Lee YS, Kislinger T, Liu SK, Fort RS, Duhagon MA

Journal of proteome research2025

DOI: 10.1021/acs.jproteome.4c00521 PMID: 39723625

Profile data last refreshed on September 25, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.

Something wrong or missing on this profile? Suggest a correction

Thomas Kislinger

Research

Latest papers

Latest funding

IFN-&#x3b3; drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.

Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome.

Protocol for N-glycoproteomic enrichment of cancer cell-surface proteins in patient-derived xenografts.

Identification of non-canonical peptides with moPepGen.

METTL3-based epitranscriptomic editing screening identifies functional m6A sites in cancers.

Dual tumour–myeloid targeting of glioblastoma with GPNMB CAR-T cells

uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target

Pan-cancer N-glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as an actionable surface target

Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma.

Multi-Omics Study Reveals Nc886/vtRNA2-1 as a Positive Regulator of Prostate Cancer Cell Immunity.

Frequent collaborators

Andrew Emili

Rama Khokha

Sheila Singh

Igor Jurisica

Jason Moffat

Fei-Fei Liu

Gelareh Zadeh

Laurie Ailles

Ming-Sound Tsao

Brian Cox

Janet Rossant

Mathieu Lupien

Farshad Nassiri

Hong Han

Gerold Schmitt-Ulms

Peter Liu

Cynthia Hawkins

Janusz Rak

Stefan Hofer

Federico Gaiti

Johann Hitzler

Marianne Koritzinsky

Parvez Vora

Geoffrey Liu

Jackek Michael Kwiecien

Frank Sicheri

Abdelsimar II Omar

Martin Olivier

Nicholas Bock

Jeffrey Greenspoon

Katie Houlahan

Kjetil Ask

IFN-γ drives long-term bone marrow niche dysfunction following doxorubicin-based chemotherapy.